• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    2/9/22 11:08:31 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No. 1 )*

     

    Artelo Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    04301G201

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [_] Rule 13d-1(b)
       
      [X] Rule 13d-1(c)
       
      [_] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.: 04301G201

     

    1.NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      
     Parian Global Management LP
      
    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      
     (a) [  ]
     (b) [  ]
      
    3.SEC USE ONLY
      
    4.CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
      
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
    5.SOLE VOTING POWER
      
     0
      
    6.SHARED VOTING POWER
      
     0
      
    7.SOLE DISPOSITIVE POWER
      
     0
      
    8.SHARED DISPOSITIVE POWER
      
     0
      
    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
      
    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     [  ]
     
    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
      
    12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IA

     

     

     

     

    CUSIP No.: 04301G201

     

    1.NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      
     Parian Global Master Fund LP
      
    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      
     (a) [  ]
     (b) [  ]
      
    3.SEC USE ONLY
      
    4.CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Cayman Islands
      
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
      
    5.SOLE VOTING POWER
      
     0
      
    6.SHARED VOTING POWER
      
     0
      
    7.SOLE DISPOSITIVE POWER
      
     0
      
    8.SHARED DISPOSITIVE POWER
      
     0
      
    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
      
    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     [  ]
      
    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
      
    12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     PN

     

     

     

     

    CUSIP No.: 04301G201

     

    1.NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      
     CCZG LLC
      
    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      
     (a) [  ]
     (b) [  ]
      
    3.SEC USE ONLY
      
    4.CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
      
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
      
    5.SOLE VOTING POWER
      
     0
      
    6.SHARED VOTING POWER
      
     0
      
    7.SOLE DISPOSITIVE POWER
      
     0
      
    8.SHARED DISPOSITIVE POWER
      
     0
      
    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
      
    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     [  ]
      
    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
      
    12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     HC

     

     

     

     

    CUSIP No.: 04301G201

     

    1.NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      
     Zachary C. Miller
      
    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      
     (a) [  ]
     (b) [  ]
      
    3.SEC USE ONLY
      
    4.CITIZENSHIP OR PLACE OF ORGANIZATION
      
     United States
      
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
      
    5.SOLE VOTING POWER
      
     0
      
    6.SHARED VOTING POWER
      
     0
      
    7.SOLE DISPOSITIVE POWER
      
     0
      
    8.SHARED DISPOSITIVE POWER
      
     0
      
    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     0
      
    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     [  ]
      
    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     0%
      
    12.TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     HC, IN

     

     

     

     

    CUSIP No.: 04301G201

     

    Item 1. (a).Name of Issuer:
        
       Artelo Biosciences, Inc.
        
    (b).Address of issuer’s principal executive offices:
       
      888 Prospect St., Suite 210
      La Jolla, CA 92037
       
    Item 2.(a).Name of person filing:
       
      Parian Global Management LP
      Parian Global Master Fund LP
      CCZG LLC
      Zachary C. Miller
       
    (b).Address or principal business office or, if none, residence:
       
      c/o Parian Global Management LP
      61 Pound Ridge Road
      Pound Ridge, NY 10576
       
    (c).Citizenship:
       
      Parian Global Management LP - Delaware
      Parian Global Master Fund LP – Cayman Islands
      CCZG LLC – Delaware
      Zachary C. Miller – United States
       
     (d).Title of class of securities:
       
      Common Stock, $0.001 par value per share
       
     (e).CUSIP No.:
       
      04301G201

     

     

     

     

    CUSIP No.: 04301G201

     

    Item 3.If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
      
     N/A
      
    Item 4.Ownership.
      
     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:
       
      Parian Global Management LP – 0
      Parian Global Master Fund LP - 0
      CCZG LLC – 0
      Zachary C. Miller – 0
       
    (b)Percent of class:
       
      Parian Global Management LP –0%
      Parian Global Master Fund LP – 0%
      CCZG LLC – 0%
      Zachary C. Miller – 0%
       
    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote
       
      Parian Global Management LP – 0
      Parian Global Master Fund LP - 0
      CCZG LLC – 0
      Zachary C. Miller – 0
       
    (ii)Shared power to vote or to direct the vote
       
      Parian Global Management LP – 0
      Parian Global Master Fund LP - 0
      CCZG LLC – 0
      Zachary C. Miller – 0
       
    (iii)Sole power to dispose or to direct the disposition of
       
      Parian Global Management LP – 0
      Parian Global Master Fund LP - 0
      CCZG LLC – 0
      Zachary C. Miller – 0
       
    (iv)Shared power to dispose or to direct the disposition of
       
      Parian Global Management LP – 0
      Parian Global Master Fund LP 0
      CCZG LLC – 0
      Zachary C. Miller –0

     

     

     

     

    CUSIP No.: 04301G201

     

    Item 5.Ownership of Five Percent or Less of a Class.
      
     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [X]
      
      
      
    Item 6.Ownership of More Than Five Percent on Behalf of Another Person.
      
     If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
      
     N/A
      
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      
     If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
      
     N/A
      
    Item 8.Identification and Classification of Members of the Group.
      
     If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
      
     N/A
      
    Item 9.Notice of Dissolution of Group.
      
     Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
      
     N/A
      
    Item 10.Certification.
      
     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    CUSIP No.: 04301G201

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 9, 2022  
       
      Parian Global Management LP
      By: CCZG LLC, its General Partner
       
      By: /s/ Zachary C. Miller
        Zachary C. Miller, Managing Member
       
      Parian Global Master LP
      By: Parian Global Management LP, its Investment Manager
      By: CCZG LLC, the General Partner of the Investment Manager
       
      By: /s/ Zachary C. Miller
        Zachary C. Miller, Managing Member  
       
      CCZG LLC
       
      By: /s/ Zachary C. Miller
        Managing Member
       
      Zachary C. Miller
       
      By: /s/ Zachary C. Miller
        Zachary C. Miller

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
    Get the next $ARTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Favorito Tamara A

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:24:07 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Matsui Connie

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres, CEO, CFO, Treas & Secr Gorgas Gregory D.

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

      SOLANA BEACH, Caif., May 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended March 31, 2025. Business Highlights: ART26.12: The first selective fatty acid binding protein 5 (FABP5) inhibitor to enter clinical trials completed enrollment of its Phase I safety study in healthy volunteers. Data readout remains on track for the second quarter of 2025.Newly published peer-reviewed

      5/13/25 8:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

      SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK. In the course of the presentation, titled "Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications," Mr. Osborn will discuss an analysis of multiple datasets across

      3/31/25 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

      SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024. Business Highlights: ART26.12: Phase I study is on track for completion in Q2 2025.ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the end of Q2 2025.ART12.11: Substantial progress has been made toward initiation of human studies with an oral solid dosage form

      3/3/25 8:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

      11/1/21 6:29:39 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

      LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

      2/12/21 7:33:23 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Artelo Biosciences with a new price target

      Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00

      2/12/21 7:14:55 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    SEC Filings

    See more
    • Artelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/23/25 4:30:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Artelo Biosciences Inc.

      10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/13/25 8:22:40 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/1/25 4:24:33 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/23/22 4:36:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/9/22 11:08:31 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

      SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

      2/4/22 3:19:12 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

      LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

      3/9/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

      LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem

      2/16/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care